Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brain-derived neurotrophic factor plasmid DNA
- Development stage
- Unknown
- Lead developer
- University of New South Wales
- Modality
- Gene Therapies
- Administration
- Otic
01
Overview
Brain-derived neurotrophic factor plasmid DNA is a non-viral, naked plasmid DNA gene therapy developed by UNSW Sydney (Translational Neuroscience Facility) for the treatment of severe to profound sensorineural hearing loss and deafness. Delivered via close-field electroporation (gene electrotransfer) using a cochlear implant electrode array directly into the mesenchymal cells of the cochlea during surgery, the plasmid encodes both brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3). Once transfected, these cells produce BDNF and NT-3, which act as agonists on the TrkB and TrkC receptors of cochlear spiral ganglion cells, stimulating the regrowth of spiral ganglion peripheral neurites toward the cochlear implant electrodes to improve the neural interface.
- Brand names
- BaDGE
- Other names
- pFAR4-CMVp-BDNF-IRES-NT3pFAR-4-CMVp-BDNF-IRES-NT3pFAR 4-CMVp-BDNF-IRES-NT3pFAR4-CMVp-BDNF-NT3pFAR-4-CMVp-BDNF-NT3pFAR 4-CMVp-BDNF-NT3BDNF/NT-3 plasmid DNABDNF plasmid DNA
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)
Beyond the preview
Go deeper on brain-derived neurotrophic factor plasmid DNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brain-derived neurotrophic factor plasmid DNA.